Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease

Natalie Kaplan, Aya Vituri, Amos D. Korczyn, Oren S. Cohen, Rivka Inzelberg, Gilad Yahalom, Evgenia Kozlova, Roni Milgrom, Yael Laitman, Eitan Friedman, Saharon Rosset, Sharon Hassin-Baer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Levodopa-induced dyskinesias (LID) present a common but elusive complication of levodopa therapy in Parkinson's disease (PD). In order to identify genetic factors associated with LID, 352 (213 males) levodopa-treated Israeli PD patients were genotyped for 34 polymorphisms within three candidate genes affecting dopaminergic activity and synaptic plasticity: dopamine transporter gene (DAT1 or SLC6A3) [14 single nucleotide polymorphisms (SNPs) and 40-bp variable number tandem repeat (VNTR)], DRD2 [11 SNPs and dinucleotide CA short tandem repeat (STR)], and BDNF (7 SNPs). A comparison of patients with and without LID was performed by applying a time-oriented approach, with survival analyses evaluating LID development hazard rate over time [Cox proportional hazards and accelerated failure time (AFT) lognormal models]. Overall, 192 (54.5 %) participants developed LID, with a mean latency of 5.0 (±4.5) years. After adjusting for gender, age at PD onset, duration of symptoms prior to levodopa exposure, and multiple testing correction, one SNP in SLC6A3 (with 81 % genotyping success) was significantly associated with LID latency: the C allele of the rs393795 extended the time to LID onset, time ratio=4.96 (95 % CI, 2.3-10.9; p=4.1×10-5). This finding should be validated in larger, ethnically diverse PD populations, and the biological mechanism should be explored.

Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalJournal of Molecular Neuroscience
Issue number2
StatePublished - Jun 2014


FundersFunder number
Bharier Medical Fund
Mariana and George Saia Foundation
Tel Aviv University


    • BDNF
    • DRD2
    • Dopamine transporter gene (SLC6A3)
    • Levodopa-induced dyskinesias (LID)
    • Parkinson's disease
    • Single nucleotide polymorphism (SNP)


    Dive into the research topics of 'Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease'. Together they form a unique fingerprint.

    Cite this